Business Description
Lipella Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US53630L2097
Share Class Description:
LIPO: Ordinary SharesTotal Employee Number:
7Description
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.03 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -17.56 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.3 | |||||
3-Year EBITDA Growth Rate | -22.7 | |||||
3-Year EPS without NRI Growth Rate | -22.6 | |||||
3-Year FCF Growth Rate | -39.9 | |||||
3-Year Book Growth Rate | -7.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.92 | |||||
9-Day RSI | 41.11 | |||||
14-Day RSI | 44.48 | |||||
3-1 Month Momentum % | 129.89 | |||||
6-1 Month Momentum % | -53.22 | |||||
12-1 Month Momentum % | -90.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.24 | |||||
Quick Ratio | 3.24 | |||||
Cash Ratio | 2.89 | |||||
Days Payable | 47.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19 | |||||
Shareholder Yield % | -583.11 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -565.67 | |||||
Operating Margin % | -1009.33 | |||||
Net Margin % | -994.4 | |||||
EBITDA Margin % | -996.83 | |||||
FCF Margin % | -890.86 | |||||
OCF Margin % | -890.86 | |||||
ROE % | -228.03 | |||||
ROA % | -169.1 | |||||
ROIC % | -2765.85 | |||||
3-Year ROIIC % | 1906.63 | |||||
ROC (Joel Greenblatt) % | -3387.83 | |||||
ROCE % | -220.2 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.15 | |||||
PB Ratio | 0.2 | |||||
Price-to-Tangible-Book | 0.2 | |||||
EV-to-EBIT | 0.24 | |||||
EV-to-Forward-EBIT | -0.61 | |||||
EV-to-EBITDA | 0.24 | |||||
EV-to-Revenue | -2.41 | |||||
EV-to-FCF | 0.27 | |||||
Price-to-GF-Value | 0.01 | |||||
| Price-to-Net-Current-Asset-Value | 0.25 | |||||
| Price-to-Net-Cash | 0.3 | |||||
Earnings Yield (Greenblatt) % | 416.67 | |||||
FCF Yield % | -1591.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:LIPO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lipella Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.536 | ||
| EPS (TTM) ($) | -2.42 | ||
| Beta | 1.652 | ||
| 3-Year Sharpe Ratio | -0.74 | ||
| 3-Year Sortino Ratio | -1.04 | ||
| Volatility % | 160.45 | ||
| 14-Day RSI | 44.48 | ||
| 14-Day ATR ($) | 0.018701 | ||
| 20-Day SMA ($) | 0.08526 | ||
| 12-1 Month Momentum % | -90.36 | ||
| 52-Week Range ($) | 0.0197 - 0.817 | ||
| Shares Outstanding (Mil) | 4.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lipella Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lipella Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.125:1 Stock Split | 2024-11-08 | 2.50 (-5.15%) |
Show
Entries
Lipella Pharmaceuticals Inc Frequently Asked Questions
What is Lipella Pharmaceuticals Inc(LIPO)'s stock price today?
The current price of LIPO is $0.07. The 52 week high of LIPO is $0.82 and 52 week low is $0.02.
When is next earnings date of Lipella Pharmaceuticals Inc(LIPO)?
The next earnings date of Lipella Pharmaceuticals Inc(LIPO) is .
Does Lipella Pharmaceuticals Inc(LIPO) pay dividends? If so, how much?
Lipella Pharmaceuticals Inc(LIPO) does not pay dividend.
Guru Commentaries on OTCPK:LIPO
No articles.
Press Release
Articles on Lipella Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers